A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products
Key News
OCTOBER 2, 2023
Notice of Extraordinary General Meeting on October 26
SEPTEMBER 29, 2023
Orexo is celebrating 10 years on the US Pharma market
SEPTEMBER 26, 2023
Our skilled RnD team in Uppsala, Sweden, is looking for a master student to write a thesis paper on drug delivery.
To read all NEWS go to Media in the top menu
Key financial figures
Group net revenue
634 MSEK
Last Twelve Months, Q322-Q223
Group EBITDA
-121 MSEK
Last Twelve Months, Q322-Q223
US Pharma segment EBIT
293 MSEK
Last Twelve Months, Q322-Q223
Cash position
251 MSEK
Q223